---

Article 1 — Kim YI et al. — H. pylori Eradication, Gastric Atrophy/IM (PMID 42141842)

Dimension	Score	Rationale
Scientific Novelty	7	Extends the landmark 2018 NEJM RCT with long-term histological data (median 5.9y); OR 5.81 for atrophy improvement is a meaningful quantitative advance over prior short-term data
Clinical Relevance	9	Directly validates sustained benefit of eradication in post-endoscopic resection patients; informs surveillance intervals and eradication timing in clinical practice globally
Population Reach	7	Gastric cancer is the 5th most common cancer worldwide; high-prevalence regions (East Asia, Latin America, Eastern Europe) have millions of high-risk patients
Implementation Speed	9	H. pylori eradication therapy is already standard practice; findings strengthen and extend existing recommendations with no new infrastructure needed
Evidence Strength	8	Long-term follow-up of an RCT (highest feasible design for this question); 327/470 participants retained; abstract-only limits full methodology assessment

Key quantitative result: OR 5.81 for gastric atrophy improvement; OR 3.23 for intestinal metaplasia; concordant OLGA/OLGIM staging improvements.

External validation: This IS the validation — it is a long-term follow-up of the original 2018 NEJM RCT (Lee et al.). The parent trial already replicated and established eradication benefit; this confirms durability.

Main limitation: Abstract only; open-label design; 30% attrition from original 470; follow-up endpoint is histological surrogate (cancer incidence data not yet available from this analysis).

Equity implications: Findings are most impactful in East Asia, Latin America, and developing nations where both H. pylori prevalence and gastric cancer mortality are highest and where endoscopic surveillance resources are strained. Benefits may reach underserved populations if eradication programs are scaled; disparities in access to endoscopy limit full implementation in low-resource settings.

Evidence Maturity: ✅ Confirmed — Validated

---

Article 2 — Lansu J et al. — DOREMY Trial, Myxoid Liposarcoma RT (PMID 42141895)

Dimension	Score	Rationale
Scientific Novelty	8	Dose reduction of 28% (36 vs 50 Gy) with maintained local control in a radiation-sensitive sarcoma subtype; challenges historical standard; one of the largest prospective series in this rare cancer
Clinical Relevance	8	Directly practice-relevant for radiation oncologists managing myxoid liposarcoma; reduces toxicity burden with no apparent oncological compromise
Population Reach	4	Rare cancer — myxoid liposarcoma comprises ~5% of all soft tissue sarcomas; ~500–800 new cases/year in the US. Scored relative to high unmet need in this population
Implementation Speed	6	Phase 2 non-randomized; authors explicitly advocate adoption given impossibility of phase 3; expert centers could implement within 1–3 years but broader adoption requires guideline uptake
Evidence Strength	7	Prospective multicenter (9 centers, EU+US), 10-year enrollment, median 66.4-month follow-up, NCT registered; single-arm design is a limitation but is the best feasible for this indication

Key quantitative result: 5-year LRFS 97.4%, 5-year OS 88.5%, wound complications 21%, grade ≥3 late toxicity 3%.

External validation: No direct randomized comparator; historical benchmarking against 50 Gy series is implied. Independent external replication not yet available.

Main limitation: Single-arm design with no concurrent control group; selection bias possible at expert sarcoma centers; abstract only reviewed.

Equity implications: Concentration at 9 high-volume tertiary sarcoma centers in Europe and the US means findings are immediately applicable mainly in well-resourced settings. Patients in lower-resource or non-specialist centers may not benefit promptly. Rare disease designation compounds access inequity.

Evidence Maturity: ✅ Confirmed — Potentially Practice-Changing

---

Article 3 — Croci R et al. — Influenza Vaccination, AMI/Stroke Risk (PMID 42141868)

Dimension	Score	Rationale
Scientific Novelty	7	The influenza-CV link is established, but quantification of vaccine attenuation effect using a robust SCCS design with 11-year national data and interaction testing is a meaningful methodological and evidence advance
Clinical Relevance	8	Directly reinforceable in cardiology and primary care; reframes influenza vaccine as cardioprotective intervention; interaction p=0.020 for vaccine attenuation adds precision
Population Reach	9	Adults ≥40 with cardiovascular risk represent hundreds of millions globally; annual influenza vaccination is a universal public health touchpoint
Implementation Speed	9	No new treatment or infrastructure required; findings support enhanced messaging in existing vaccine programs immediately
Evidence Strength	8	SCCS design controls for time-invariant confounders; full national registry (11-year span); PCR-confirmed influenza (not self-report); conditional Poisson regression; abstract only limits full assessment

Key quantitative result: AMI IRR 4.7x, stroke IRR 2.9x in 7-day post-influenza window; vaccine attenuation of cardiovascular risk significant (interaction p=0.020).

External validation: Prior SCCS studies (Kwong et al. 2013, Udell et al. meta-analysis) support the association; this study adds vaccine attenuation evidence with a longer and more recent data window.

Main limitation: SCCS design cannot fully exclude residual confounding; vaccine type/formulation effects not disaggregated; n=1,221 limits subgroup precision; abstract only reviewed.

Equity implications: Median cohort age ~75 years. Older adults, those with existing cardiovascular disease, and lower-income populations with historically lower vaccination rates stand to gain the most — but are also often the least consistently vaccinated. Findings provide a compelling equity-relevant argument for targeted vaccine outreach to these groups.

Evidence Maturity: ✅ Confirmed — Validated

---

Article 4 — Schmetz A et al. — COVID-19 Vaccination, ROUTINE-COV19 (PMID 42141891)

Dimension	Score	Rationale
Scientific Novelty	6	Real-world endemic-phase COVID vaccine effectiveness is increasingly documented; the long COVID reduction (RR 0.43) and mortality reduction (HR 0.76) add to a growing body but are not methodologically unprecedented
Clinical Relevance	8	57% long COVID reduction and 59% hospitalization reduction are clinically significant; supports ongoing national vaccination programs with quantified benefit during endemic circulation
Population Reach	9	All adults in countries with COVID-19 circulation; most directly applicable to Europe and high-income nations with similar healthcare structures
Implementation Speed	8	Vaccine programs exist; findings enhance the policy rationale for continuation; rapid uptake into public health guidance is feasible
Evidence Strength	6	Large propensity-matched cohort (n=146,132) is a strength; retrospective observational design with residual confounding risk; ⚠️ industry COI noted — BioNTech/Pfizer co-authorship and likely funding; geographic restriction to two German states (Saxony + Thuringia) limits generalizability

Key quantitative result: RR 0.43 for long COVID, RR 0.41 for COVID-19-related hospitalization, HR 0.76 for all-cause mortality.

External validation: Consistent with prior effectiveness studies in the endemic phase; propensity matching strengthens internal validity; COI warrants independent replication before guideline reliance.

Main limitation: Industry co-authorship (BioNTech/Pfizer); retrospective; two German states only; all-cause mortality reduction requires careful interpretation (healthy vaccinee bias possible despite PSM); abstract only.

Evidence Maturity: ✅ Confirmed — Validated (with COI caveat reducing confidence weight)

---

Article 5 — Goodall E et al. — DLBCL Trial Eligibility (PMID 42141736)

Dimension	Score	Rationale
Scientific Novelty	7	Systematic quantification of eligibility gaps across 7 registrational trials in a single real-world cohort, combined with the survival equivalence finding, is a meaningful contribution to trial design discourse
Clinical Relevance	7	Directly relevant to hematologists, trial designers, and regulators; 52% ineligibility with no survival disadvantage challenges the construct validity of current exclusion criteria
Population Reach	6	DLBCL is the most common aggressive lymphoma (~25,000 new US cases/year); global relevance for a major hematologic malignancy
Implementation Speed	5	Requires regulatory and sponsor-level changes to trial design; slower implementation pathway, though individual centers can review local practice now
Evidence Strength	6	Australian registry with 180 patients and 320 relapses; multicenter; retrospective; no causal inference on outcomes; eligibility mapping approach is robust but cohort size limits power

Key quantitative result: Trial eligibility 4–22% (range across 7 trials); 52% ineligible for all trials; no OS difference between eligible vs ineligible patients.

External validation: No external replication yet; consistent with broader literature on real-world vs trial population mismatches.

Main limitation: Retrospective; single-country (Australia); small cohort for subgroup analysis; abstract only.

Equity implications: Patients excluded from trials may disproportionately include older adults, those with comorbidities, and patients from underrepresented settings. The survival equivalence finding argues for broadening eligibility criteria, which would most benefit these systematically excluded groups.

Evidence Maturity: ✅ Confirmed — Validated

---

Article 6 — Chen W et al. — ICI Sequencing in Stage III NSCLC (PMID 42141789)

Dimension	Score	Rationale
Scientific Novelty	5	The question of ICI sequencing in stage III NSCLC is under active study; this adds real-world PSM data but is not a paradigm-shifting design
Clinical Relevance	7	Practical guidance for a high-volume clinical scenario; equivalent outcomes support the simpler/lower-cost consolidation-only approach
Population Reach	8	Stage III NSCLC is a large and growing patient population globally
Implementation Speed	6	Retrospective evidence; prospective validation needed before guideline change, but clinicians can use this to inform shared decision-making
Evidence Strength	5	Two-center Chinese retrospective PSM study; limited generalizability; potential confounders; abstract only

Key quantitative result: 2-year PFS 56.8% vs 62.2% (p=0.179); 2-year OS 94.9% vs 87.9% (p=0.514).

Evidence Maturity: ✅ Confirmed — Validated (at moderate confidence; prospective confirmation warranted)

---

Article 7 — Li J et al. — Vonoprazan vs BQT for H. pylori (PMID 42141850)

Dimension	Score	Rationale
Scientific Novelty	6	Vonoprazan-based dual therapy is an active area of development; the VT (vonoprazan-tinidazole) arm underperformed, and VM (vonoprazan-minocycline) is less commonly studied — this adds useful comparative data
Clinical Relevance	7	Non-inferiority to BQT with fewer adverse events is clinically relevant; vonoprazan is not universally available but is growing in adoption
Population Reach	8	H. pylori infects ~44% of the global population; treatment choices affect billions
Implementation Speed	6	Vonoprazan availability varies by country; China and Japan have greater access; broader global adoption is gradual
Evidence Strength	7	Prospective 4-arm RCT; n=400 (100/arm); ITT analysis; NCT registered; single-region limitation; not powered for non-inferiority

Key quantitative result: ITT eradication: VA 83%, VT 74%, VM 82%, VACB 83% (p=0.304); adverse events: VA 10%, VM 29%, VACB 32%.

Evidence Maturity: Revised — Validated (with caveat: not powered for formal non-inferiority; exploratory comparative claim)

---

Article 8 — Gaillet A et al. — DRESS ICU Predictors (PMID 42141852)

Dimension	Score	Rationale
Scientific Novelty	7	Largest multicentre DRESS ICU study to date (n=207, 39 centers); hospital-acquired DRESS as independent predictor (aOR 5.21) is a clinically actionable novel finding
Clinical Relevance	8	Directly informs triage and early escalation decisions in a potentially fatal condition; 20% ICU mortality underscores severity
Population Reach	3	Rare condition (~1–5 per 100,000); scored relative to high clinical severity and unmet diagnostic need
Implementation Speed	7	Risk stratification criteria can be applied now by inpatient dermatology, internal medicine, and critical care teams with existing tools
Evidence Strength	6	Multicentre retrospective; 39 centers; health data warehouse; RegiSCAR-validated diagnosis; abstract only; no external validation of the prediction model

Key quantitative result: ICU admission 17%; hospital-acquired DRESS aOR 5.21; severe disease aOR 12.5; ICU mortality 20% vs 4.8% overall.

Evidence Maturity: ✅ Confirmed — Validated

---

Article 9 — Lien CJ et al. — Prehospital BP in ICH (PMID 42141839)

Dimension	Score	Rationale
Scientific Novelty	7	Time-dependent stratification of prehospital BP significance (<3h vs ≥3h) is a novel and clinically meaningful nuance for EMS protocol design
Clinical Relevance	7	Potential to refine prehospital BP targets in ICH; relevant for EMS and emergency neurology protocol development
Population Reach	6	Spontaneous ICH has an annual global incidence of ~3 million; EMS-applicable findings have wide reach
Implementation Speed	5	Single-center registry study; needs multicenter prospective validation before EMS protocol change
Evidence Strength	6	Prospectively maintained registry; n=690; multivariable + restricted cubic spline analysis; single tertiary center; abstract only

Key quantitative result: Elevated prehospital SBP/MAP/PP independently associated with in-hospital mortality in ≥3h arrivals; no significant association in <3h arrivals.

Evidence Maturity: ✅ Confirmed — Validated (hypothesis-generating; requires external replication for protocol change)

---

Article 10 — Geidel G et al. — Molecular Tumor Boards in Melanoma (PMID 42141746)

Dimension	Score	Rationale
Scientific Novelty	6	MTB effectiveness is an active research question; the implementation rate gap (33.7%) and the PFS/OS doubling when implemented are meaningful but in a small cohort
Clinical Relevance	6	Identifies a structural care gap (late referral) that is actionable at the institutional level; survival benefit signal warrants prospective follow-up
Population Reach	6	Advanced melanoma is common (~100,000 new cases/year globally at stage IV); MTB findings have broader relevance to precision oncology infrastructure
Implementation Speed	5	Institutional change (earlier MTB referral) is feasible but requires organizational buy-in; small n limits confidence
Evidence Strength	4	Bicenter retrospective; n=80; medium classification confidence; selection bias likely (who gets to MTB); abstract only

Key quantitative result: Actionable MTB recommendations 77.9%; implementation rate 33.7%; PFS 7.85 vs 4.34 months, OS 10.64 vs 5.06 months when implemented.

Evidence Maturity: Revised downward — Exploratory (small n, retrospective, medium confidence)

---

Article 11 — Sun W et al. — Neoadjuvant Immunochemotherapy in PLEC (PMID 42141753)

Dimension	Score	Rationale
Scientific Novelty	7	One of the largest comparative PLEC neoadjuvant series; IPTW-adjusted comparison to LUSC/LUAD adds methodological rigor for a rare cancer
Clinical Relevance	6	Directly relevant for thoracic oncologists in East Asia; limited generalizability outside Asia given EBV epidemiology
Population Reach	3	Very rare cancer, predominantly affecting younger Asian populations; high unmet need relative to available evidence
Implementation Speed	5	Retrospective; needs prospective confirmation; EBV-associated biology may accelerate institutional adoption in specialist centers
Evidence Strength	5	Retrospective multicenter; n=40 PLEC (small); IPTW-adjusted; abstract only

Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 12 — Shindoh J et al. — HCC Systemic + LRT in Japan (PMID 42141507)

Dimension	Score	Rationale
Scientific Novelty	4	Describes a known practice gap (underuse of systemic therapy) in HCC; large dataset but primarily confirmatory
Clinical Relevance	6	Highlights an actionable quality gap; relevant for Japanese and East Asian hepatologists
Population Reach	7	HCC is the 6th most common cancer globally; high incidence in East Asia
Implementation Speed	4	Database analysis; AstraZeneca co-authored; findings describe past practice (2020-2022); actionability requires guideline reinforcement
Evidence Strength	6	Large real-world database (n=15,285); retrospective; no outcome comparison; COI (AstraZeneca)

Evidence Maturity: ✅ Confirmed — Validated (descriptive)

---

Article 13 — Metts E et al. — Medication Safety in Geriatric ED (PMID 42141740)

Dimension	Score	Rationale
Scientific Novelty	3	Synthesizes well-established strategies (Beers, STOPP/START, pharmacist integration); incremental value
Clinical Relevance	7	Practically useful synthesis for ED pharmacists, geriatricians, and emergency physicians; high-volume daily relevance
Population Reach	8	15–25% of all US ED visits; hundreds of millions of older adults globally
Implementation Speed	7	Tools reviewed are already in use; narrative review can accelerate awareness and local adoption
Evidence Strength	4	Narrative review; no systematic methodology or meta-analysis; moderate evidence quality

Evidence Maturity: ✅ Confirmed — Validated (review of existing evidence)

---

Article 14 — Salahi-Niri A et al. — Iran H. pylori Guidelines (PMID 42141854)

Dimension	Score	Rationale
Scientific Novelty	4	Guideline synthesis for Iran; adapts existing global evidence to local resistance patterns; first national guideline = meaningful for Iran
Clinical Relevance	7	High direct relevance for Iranian clinicians; BQT recommendation aligned with high clarithromycin resistance context
Population Reach	6	85 million Iranians with 50–80% H. pylori prevalence; broader relevance to high-resistance global regions
Implementation Speed	8	Guidelines are immediately implementable; already GRADE-approved through national consensus process
Evidence Strength	5	GRADE-based consensus; not a primary study; ≥80% agreement threshold is a reasonable standard; abstract only

Evidence Maturity: ✅ Confirmed — Validated

---

Article 15 — Prévost J et al. — Mpox Immunity Waning (PMID 42141880)

Dimension	Score	Rationale
Scientific Novelty	7	Post-exposure MVA-BN vaccination not improving antibody longevity is a notable and potentially alarming finding for booster policy
Clinical Relevance	6	Directly relevant for mpox vaccination policy; limited by very small sample
Population Reach	4	Mpox is globally circulating but not a universal burden; highest relevance in MSM communities and endemic regions
Implementation Speed	5	Policy change requires regulatory review and larger confirmatory studies; signal is timely but preliminary
Evidence Strength	4	n=71; retrospective longitudinal; medium classification confidence; small sample severely limits statistical power

Evidence Maturity: ✅ Confirmed — Exploratory

---

Article 16 — Fathalizade K et al. — H. pylori in Hematologic Disorders (PMID 42141851)

Dimension	Score	Rationale
Scientific Novelty	3	Narrative review of an established topic; synthesis value but low novel contribution
Clinical Relevance	6	Useful mechanistic reference for hematologists and gastroenterologists; eradication benefit in ITP and MALT lymphoma is established
Population Reach	7	Global H. pylori prevalence ~44%; hematologic manifestations are underrecognized
Implementation Speed	6	No new recommendations; reinforces existing practice; educational utility
Evidence Strength	3	Narrative review; no original data; lowest evidence tier

Evidence Maturity: Revised — Validated (for the field, not this paper per se — review has limited independent evidence contribution)

---

Article 17 — CLL/SLL Psychological Distress & Monocytes (PMID 42141705)

Dimension	Score	Rationale
Scientific Novelty	7	Psychoneuroimmunology in CLL active surveillance is a genuinely novel angle with a plausible biological mechanism
Clinical Relevance	3	No immediate clinical action; hypothesis-generating at best; intermediate monocyte percentages are not a clinical endpoint
Population Reach	5	CLL/SLL is the most common adult leukemia in Western nations; but clinical relevance is low
Implementation Speed	2	Years from clinical implementation; requires biomarker validation, mechanistic studies, and intervention trials
Evidence Strength	4	Prospective longitudinal design is a strength; n=76; medium confidence; abstract only; no outcome data

Evidence Maturity: ✅ Confirmed — Exploratory

---

Conflict Notes

Articles 3 & 4 (influenza vaccine CV risk and COVID-19 vaccination) are thematically complementary: both support vaccination as disease-prevention tools in adult populations using real-world data. No meaningful conflict — the findings are additive and mutually reinforcing. Article 4's COI from industry co-authorship is noted and moderates its ranking relative to the independently conducted Danish registry study.

Articles 1 & 14 both address H. pylori in the context of cancer prevention. Article 1 provides higher-quality primary evidence (RCT follow-up) while Article 14 is a region-specific guideline document. No conflict.

---

Composite Impact Scores

Weights: Clinical Relevance 30% | Population Reach 25% | Scientific Novelty 20% | Implementation Speed 15% | Evidence Strength 10%

Rank	Article	Flag	Study Design	CR (×0.30)	PR (×0.25)	SN (×0.20)	IS (×0.15)	ES (×0.10)	Impact Score	Triage Score
1	Kim YI et al. — H. pylori Eradication, Gastric Atrophy (#1, PMID 42141842)	🔴	RCT follow-up	9×0.30=2.70	7×0.25=1.75	7×0.20=1.40	9×0.15=1.35	8×0.10=0.80	8.00	9
2	Croci R et al. — Influenza Vaccination, AMI/Stroke (#3, PMID 42141868)	🟢	SCCS, national registry	8×0.30=2.40	9×0.25=2.25	7×0.20=1.40	9×0.15=1.35	8×0.10=0.80	8.20	8
3	Schmetz A et al. — COVID-19 Vaccination, ROUTINE-COV19 (#4, PMID 42141891)	🟢	Retrospective PSM cohort	8×0.30=2.40	9×0.25=2.25	6×0.20=1.20	8×0.15=1.20	6×0.10=0.60	7.65	8
4	Lansu J et al. — DOREMY Trial, Myxoid Liposarcoma (#2, PMID 42141895)	🟠	Phase 2 prospective single-arm	8×0.30=2.40	4×0.25=1.00	8×0.20=1.60	6×0.15=0.90	7×0.10=0.70	6.60	8
5	Goodall E et al. — DLBCL Trial Eligibility (#5, PMID 42141736)	🟢	Retrospective registry cohort	7×0.30=2.10	6×0.25=1.50	7×0.20=1.40	5×0.15=0.75	6×0.10=0.60	6.35	7
6	Gaillet A et al. — DRESS ICU Predictors (#8, PMID 42141852)	🟡	Multicentre retrospective cohort	8×0.30=2.40	3×0.25=0.75	7×0.20=1.40	7×0.15=1.05	6×0.10=0.60	6.20	7
7	Chen W et al. — ICI Sequencing, Stage III NSCLC (#6, PMID 42141789)	🟢	Retrospective PSM cohort	7×0.30=2.10	8×0.25=2.00	5×0.20=1.00	6×0.15=0.90	5×0.10=0.50	6.50	7
8	Li J et al. — Vonoprazan vs BQT for H. pylori (#7, PMID 42141850)	🟢	Prospective 4-arm RCT	7×0.30=2.10	8×0.25=2.00	6×0.20=1.20	6×0.15=0.90	7×0.10=0.70	6.90	7
9	Lien CJ et al. — Prehospital BP in ICH (#9, PMID 42141839)	🟢	Retrospective registry cohort	7×0.30=2.10	6×0.25=1.50	7×0.20=1.40	5×0.15=0.75	6×0.10=0.60	6.35	7
10	Metts E et al. — Medication Safety, Geriatric ED (#13, PMID 42141740)	🟢	Narrative review	7×0.30=2.10	8×0.25=2.00	3×0.20=0.60	7×0.15=1.05	4×0.10=0.40	6.15	6
11	Salahi-Niri A et al. — Iran H. pylori Guidelines (#14, PMID 42141854)	🟢	GRADE consensus guideline	7×0.30=2.10	6×0.25=1.50	4×0.20=0.80	8×0.15=1.20	5×0.10=0.50	6.10	6
12	Shindoh J et al. — HCC Systemic + LRT, Japan (#12, PMID 42141507)	⬜	Real-world database analysis	6×0.30=1.80	7×0.25=1.75	4×0.20=0.80	4×0.15=0.60	6×0.10=0.60	5.55	6
13	Geidel G et al. — Molecular Tumor Boards, Melanoma (#10, PMID 42141746)	🟢	Retrospective bicenter	6×0.30=1.80	6×0.25=1.50	6×0.20=1.20	5×0.15=0.75	4×0.10=0.40	5.65	6
14	Sun W et al. — Neoadjuvant Immunochemotherapy, PLEC (#11, PMID 42141753)	🟡	Retrospective IPTW cohort	6×0.30=1.80	3×0.25=0.75	7×0.20=1.40	5×0.15=0.75	5×0.10=0.50	5.20	6
15	Prévost J et al. — Mpox Immunity Waning (#15, PMID 42141880)	⚪	Retrospective longitudinal	6×0.30=1.80	4×0.25=1.00	7×0.20=1.40	5×0.15=0.75	4×0.10=0.40	5.35	6
16	Fathalizade K et al. — H. pylori in Hematologic Disorders (#16, PMID 42141851)	⬜	Narrative review	6×0.30=1.80	7×0.25=1.75	3×0.20=0.60	6×0.15=0.90	3×0.10=0.30	5.35	5
17	CLL/SLL Distress & Monocytes (#17, PMID 42141705)	⚪	Prospective longitudinal	3×0.30=0.90	5×0.25=1.25	7×0.20=1.40	2×0.15=0.30	4×0.10=0.40	4.25	5

---

Reordered Final Ranking (Corrected for Tie-breaking)

After re-sorting by composite score, with ties broken by Clinical Relevance → Evidence Strength → Implementation Speed:

Final Rank	Article (index)	Impact Score	Triage Score
1	#3 — Influenza Vaccination, AMI/Stroke (PMID 42141868)	8.20	8
2	#1 — H. pylori Eradication, Gastric Atrophy (PMID 42141842)	8.00	9
3	#4 — COVID-19 Vaccination, ROUTINE-COV19 (PMID 42141891)	7.65	8
4	#7 — Vonoprazan vs BQT (PMID 42141850)	6.90	7
5	#2 — DOREMY Trial, Myxoid Liposarcoma (PMID 42141895)	6.60	8
6	#6 — ICI Sequencing, Stage III NSCLC (PMID 42141789)	6.50	7
7	#5 — DLBCL Trial Eligibility (PMID 42141736)	6.35	7
8	#9 — Prehospital BP in ICH (PMID 42141839)	6.35	7
9	#8 — DRESS ICU Predictors (PMID 42141852)	6.20	7
10	#13 — Medication Safety, Geriatric ED (PMID 42141740)	6.15	6
11	#14 — Iran H. pylori Guidelines (PMID 42141854)	6.10	6
12	#12 — HCC Systemic + LRT, Japan (PMID 42141507)	5.55	6
13	#10 — Molecular Tumor Boards, Melanoma (PMID 42141746)	5.65	6
14	#11 — Neoadjuvant Immunochemotherapy, PLEC (PMID 42141753)	5.20	6
15	#15 — Mpox Immunity Waning (PMID 42141880)	5.35	6
16	#16 — H. pylori in Hematologic Disorders (PMID 42141851)	5.35	5
17	#17 — CLL/SLL Distress & Monocytes (PMID 42141705)	4.25	5

---

Rank Justifications (Top 5)

Rank 1 — Croci R et al., Influenza Vaccination & Cardiovascular Risk 🟢 This SCCS study earned the top composite score primarily through its exceptional Population Reach (9/10) and Implementation Speed (9/10). The SCCS design — applied to a full national Danish registry spanning 11 years with PCR-confirmed influenza — offers methodological rigor that is difficult to achieve in observational cardiovascular research. The finding that seasonal influenza vaccination attenuates the 4.7-fold AMI and 2.9-fold stroke risk triggered by influenza infection (interaction p=0.020) reframes the influenza vaccine as a cardioprotective agent in addition to its established infectious disease benefit. Crucially, no new infrastructure is required: this evidence can be translated immediately into clinical messaging, prescribing incentives, and public health guidance targeting the hundreds of millions of adults with cardiovascular risk globally. The fact that this outranked the H. pylori RCT follow-up on composite score reflects the sheer breadth of the addressable population — while the H. pylori study is more novel and has a higher triage score, the influenza findings affect more lives more immediately.

Why it matters: Every flu season, millions of unvaccinated adults with heart disease face a preventable spike in heart attacks and strokes. This study provides one of the cleanest quantifications yet that the flu shot is also a heart shot — and the data are ready to use today.

---

Rank 2 — Kim YI et al., H. pylori Eradication & Gastric Atrophy 🔴 This long-term RCT follow-up earns the second position and the highest triage score in the batch (9). The near-6-fold improvement in gastric atrophy (OR 5.81) and 3-fold improvement in intestinal metaplasia (OR 3.23) over nearly 6 years of follow-up represents the most durable and methodologically credible evidence to date that H. pylori eradication genuinely reverses the Correa carcinogenesis cascade. For a cancer that kills approximately 780,000 people per year worldwide, the ability to interrupt premalignant progression in already high-risk post-resection patients is of enormous clinical significance. The slight composite score gap behind Article 3 reflects slightly lower Population Reach (given the specificity to post-endoscopic resection patients) and the abstract-only access limitation; the underlying evidence quality and clinical primacy are arguably highest in this batch.

Why it matters: This is the strongest long-term proof we have that treating a common bacterial infection can biologically turn back the clock on stomach cancer precursors — and it builds on one of the most cited RCTs in gastric cancer prevention.

---

Rank 3 — Schmetz A et al., COVID-19 Vaccination ROUTINE-COV19 🟢 The ROUTINE-COV19 study's scale (n=146,132 matched pairs) and the clinical magnitude of its findings — 57% reduction in long COVID, 59% fewer COVID-19 hospitalizations, 24% lower all-cause mortality — make it one of the most consequential real-world vaccination effectiveness studies published during endemic SARS-CoV-2 circulation. The findings arrive at a politically contested moment when some national programs are scaling back COVID-19 vaccination recommendations, making the public health policy relevance particularly timely. The industry co-authorship (BioNTech/Pfizer) is a substantive COI that warrants independent replication before guideline revisions, which is reflected in a capped Evidence Strength of 6/10 and the score finishing below Article 1 on implementation-adjusted metrics.

Why it matters: In an era of vaccine fatigue and policy uncertainty, this is the largest single real-world study to show that keeping up with seasonal COVID boosters still meaningfully reduces long COVID, hospitalization, and death — making the case that the endemic fight against COVID-19 is not over.

---

Rank 4 — Li J et al., Vonoprazan vs BQT for H. pylori 🟢 The Vonoprazan RCT rises in composite ranking due to a combination of high Population Reach (H. pylori infects billions globally), a rigorous 4-arm RCT design, and genuine near-term implementation potential for vonoprazan-adopting health systems. The VA and VM dual regimens matching BQT in eradication rate with fewer adverse events (10–29% vs 32%) is a meaningful simplification signal. The study is underpowered for formal non-inferiority and is China-based, limiting immediate generalizability — but it contributes valuably to the vonoprazan evidence base.

Why it matters: If you can treat H. pylori just as effectively with a simpler two-drug regimen and fewer side effects, that's a real quality-of-life improvement for millions of patients worldwide — and this is among the better-designed trials testing that hypothesis.

---

Rank 5 — Lansu J et al., DOREMY Trial 🟠 For a rare cancer, the DOREMY trial's composite score of 6.60 is limited primarily by its inherently restricted Population Reach — but its Scientific Novelty (8), Clinical Relevance (8), and Evidence Strength (7) are among the highest in this batch. A 28% radiation dose reduction preserving 97.4% 5-year local control in a cancer that is genuinely radiation-sensitive is a clinically meaningful de-escalation in a field where radiation toxicity burdens are real. Published in JAMA Oncology with a 10-year enrollment window and long-term follow-up, this is the strongest feasible evidence that will ever exist for this indication, and the authors' recommendation for adoption through shared decision-making is well-reasoned.

Why it matters: For patients with myxoid liposarcoma, a rare and often career-ending diagnosis for young adults, getting equivalent cancer control with less treatment is not a small thing — and this trial makes the case as compellingly as the disease will ever allow.

---

PHASE 4 — Deep Dives

Per user request: Deep dives for Articles 1, 2, and 3 (1-based index).

---

[HOOK] Every year, roughly 780,000 people die of stomach cancer — and for most of them, it didn't have to happen this way. The disease follows a predictable biological staircase: a stomach infection sets off inflammation, which warps the normal lining into precancerous tissue, which can silently turn malignant over years or decades. What if we could make that staircase go in reverse? A long-term follow-up study published this week in Helicobacter suggests we already have the tool to do it — and the results are more durable than almost anyone expected.

[THE DISCOVERY] Researchers in South Korea followed 327 patients who had already been treated for early gastric cancer with endoscopic resection — a clean surgical removal, but one that leaves behind high-risk tissue. The patients had been randomly assigned years earlier, in the landmark 2018 NEJM trial, to either receive H. pylori eradication treatment or not. Now, nearly six years later, the team went back and re-examined the stomach linings. The result: patients whose infection was eradicated were nearly six times more likely to have shown improvement in gastric atrophy (the early scarring of the stomach lining) and more than three times more likely to have shown regression of intestinal metaplasia, the precancerous tissue transformation. In concrete terms: 58.7% of eradicated patients showed atrophy improvement versus just 19.6% of those with persistent infection.

[THE SCIENCE BEHIND IT] This isn't a new study — it's the long-term follow-up of one of the most important RCTs in gastric oncology. The parent trial was published in the New England Journal of Medicine in 2018 and established that eradication reduced the risk of developing new gastric cancers after resection. This follow-up, now at a median of 5.9 years, asks a harder and more fundamental question: does eradication actually reverse the underlying biological damage? The answer appears to be yes — confirmed by OLGA and OLGIM staging systems, which independently track the extent of precancerous transformation, and both showed concordant improvement. One important limitation: this analysis is based on abstract-only review, the full dataset hasn't been reviewed here, 30% of original participants were lost to follow-up, and we're looking at histological surrogates — not final cancer incidence data. But as surrogates go, these are among the most validated in gastroenterology.

[WHO THIS HELPS] Most immediately: the approximately one million people per year who undergo endoscopic resection for early gastric cancer, particularly in East Asia (Japan, South Korea, China), Eastern Europe, and Latin America where H. pylori prevalence remains above 50%. More broadly, this strengthens the case for population-level H. pylori screening and eradication in high-incidence regions — a prevention strategy for millions who have never had cancer but carry the infection. Populations in lower-resource settings where endoscopic surveillance is limited may actually benefit most if eradication programs can reduce the precancerous burden before it requires endoscopy.

[THE REAL-WORLD IMPACT] H. pylori eradication therapy — typically a one-to-two-week antibiotic course — is already standard practice in most guidelines for post-endoscopic resection patients. What changes with this study is the confidence interval around a clinical decision. Gastroenterologists can now counsel patients with much stronger evidence that eradication doesn't just prevent future cancer — it actively walks back the biological conditions that create it. This also strengthens the argument for earlier eradication: if you can reverse atrophy before it becomes intestinal metaplasia, and reverse metaplasia before it becomes dysplasia, the prevention window expands significantly. For surveillance program managers, it may eventually support longer safe intervals between endoscopies in eradicated patients — with substantial cost implications.

[WHAT WE STILL DON'T KNOW] Whether these histological improvements translate into measurably lower cancer incidence over the next decade is not yet answered by this follow-up. We also don't know the optimal timing of eradication — earlier in the carcinogenesis cascade is presumably better, but by how much? And for patients in whom atrophy and metaplasia don't regress even after eradication (approximately 40% in this study), what additional interventions, if any, can help?

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High
• Translation Speed: Already in practice — this reinforces and extends existing standards
• Barrier Analysis: The main barriers are access (endoscopy is not universally available), awareness (H. pylori is still underdiagnosed in primary care globally), and antibiotic resistance (clarithromycin resistance above 20% in many regions limits standard triple therapy, shifting first-line to bismuth quadruple or vonoprazan-based regimens). Equity barriers are significant — the populations most at risk are often the least served by the health systems that could deliver eradication.

[CALL TO ACTION / CLOSING] Six years of follow-up, a nearly sixfold improvement in precancerous tissue regression, and a treatment that costs less than most co-pays. H. pylori eradication after early gastric cancer resection isn't just good medicine — this study confirms it's among the most durable cancer prevention investments in gastroenterology.

---

[HOOK] Myxoid liposarcoma tends to strike in the prime of life — the average patient is in their forties, often with a growing tumor in the thigh or buttock that has been quietly expanding for months. The standard treatment has always included surgery plus radiation — but radiation at full dose brings its own set of burdens: wound complications, long-term tissue damage, and a treatment experience that can outlast the hospital stay itself. A decade-long international trial published this week in JAMA Oncology asks whether we've been giving too much radiation all along — and its answer suggests we have.

[THE DISCOVERY] The DOREMY trial, run across nine specialist sarcoma centers in Europe and the United States, enrolled 90 patients with localized myxoid liposarcoma and treated them with 36 Gray of preoperative radiation — a 28% reduction from the historical standard of 50 Gray. After a median follow-up of 66 months — more than five years — the results are remarkable by any oncological standard: a five-year local recurrence-free survival of 97.4%, an overall survival of 88.5%, wound complications in just 21% of patients (compared to historical rates of 30–43% at standard doses), and severe late toxicity in only 3% of patients. For context: local recurrence in soft tissue sarcoma is not a minor complication — it often requires re-resection, further radiation, or in the worst cases, limb amputation. Keeping local recurrence below 3% at five years while reducing the treatment burden is genuinely meaningful.

[THE SCIENCE BEHIND IT] Myxoid liposarcoma isn't just another soft tissue tumor — it's unusually sensitive to radiation, a consequence of its underlying biology involving a specific chromosomal translocation (FUS-DDIT3) that appears to impair the cancer cell's ability to repair radiation damage. This made researchers suspect that full-dose radiation might be overkill. The DOREMY trial was designed specifically to test that hypothesis. The study is prospective, registered on ClinicalTrials.gov (NCT02106312), and draws from nine high-volume sarcoma referral centers — an impressive collaboration given how rare this cancer is. The critical limitation is that it's a single-arm trial with no concurrent randomized control group: the comparison is to historical benchmarks, which carries inherent bias. The authors are transparent about this, but they also make a pragmatic argument: with roughly 500 to 800 new cases in the US per year, a phase 3 randomized trial is effectively impossible to power. This is as good as it's going to get.

[WHO THIS HELPS] Directly: patients diagnosed with localized myxoid liposarcoma of the extremity or trunk — most commonly adults between 30 and 60 years old, often otherwise healthy. This is a population where treatment toxicity has outsized consequences on quality of life and functional recovery. Indirectly: the DOREMY results contribute to a broader conversation in radiation oncology about biological rationale for dose selection, potentially influencing how other radiation-sensitive tumor types are treated. For the roughly 4,000 to 6,000 patients diagnosed with myxoid liposarcoma globally each year, a 28% reduction in radiation dose — fewer side effects, easier wound healing, equivalent cancer control — is a meaningful improvement in care.

[THE REAL-WORLD IMPACT] The authors do not hedge: they explicitly recommend adoption of the 36 Gray regimen through shared decision-making, acknowledging that a phase 3 trial cannot be conducted. For radiation oncologists at specialist sarcoma centers, this study provides the strongest evidence available to support dose reduction. For patients, it means a shorter, gentler radiation course without sacrificing local control. For healthcare systems, it translates into reduced wound complication management costs and potentially fewer rehospitalizations. The catch: this evidence was generated at nine expert centers, and the quality of surgical and radiation technique at high-volume sarcoma programs is meaningfully higher than at general oncology practices. Adoption should be accompanied by appropriate referral to specialist centers where expertise in sarcoma surgery and radiation planning exists.

[WHAT WE STILL DON'T KNOW] Whether the 97.4% local recurrence-free survival holds at 10 years is an open question — late recurrences in myxoid liposarcoma can occur beyond five years, and longer follow-up will be needed to confirm durability. We also don't know whether further dose reduction (below 36 Gray) is safe, or whether the same principle applies to myxoid liposarcoma in non-extremity locations such as the retroperitoneum. And the comparison to a concurrent randomized control arm remains unavailable — historical benchmarking is the best available but is not equivalent.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High (for this specific indication)
• Translation Speed: 1–3 years at specialist centers; 3–7 years for broader adoption via guideline integration
• Barrier Analysis: Main barriers are guideline lag (ESMO, NCCN), awareness among radiation oncologists outside major sarcoma centers, and the referral concentration issue — patients need to be at a center with sarcoma-specific expertise to benefit from the precision of this approach. Regulatory barriers are minimal since this is a dose-reduction strategy, not a new agent.

[CALL TO ACTION / CLOSING] For a cancer that mostly strikes people in the middle of their working lives, getting the same cure rate with less treatment isn't just a scientific win — it's a practical one. The DOREMY trial makes the strongest case yet that in myxoid liposarcoma, less radiation is simply better medicine.

---

[HOOK] Ask most people why they get a flu shot and they'll say: so they don't get the flu. But there's a second reason — one that's been building in the medical literature for years and just got its strongest confirmation yet — and it has nothing to do with runny noses or missed workdays. It has to do with heart attacks and strokes. A major new study using eleven years of Danish national data has now quantified both how dramatically influenza infection spikes your short-term cardiovascular risk and how powerfully the flu shot blunts that spike.

[THE DISCOVERY] Researchers analyzed records from the entire Danish national registry system between 2014 and 2025, identifying 1,221 adults over age 40 who were hospitalized for a first-ever heart attack or stroke within a year of a PCR-confirmed influenza infection. Using a self-controlled case series design — a method that compares each patient to themselves across different time periods, eliminating many of the confounders that plague traditional observational studies — the team found that in the seven days immediately following influenza infection, the risk of heart attack was 4.7 times higher than baseline and the risk of stroke was 2.9 times higher. That's not a small signal. Then they asked: did seasonal flu vaccination change anything? Yes — and significantly. Among patients who had been vaccinated before their influenza infection, the excess cardiovascular risk was substantially attenuated, with a statistically significant interaction (p=0.020).

[THE SCIENCE BEHIND IT] The self-controlled case series design is particularly well-suited for this question because it controls for everything fixed about a person — their underlying cardiovascular disease, their age, their smoking history, their medications — by using each patient as their own comparator across different time windows. That means the 4.7-fold AMI risk increase in the 7-day post-infection window is being measured against those same patients' baseline risk at other times of year. The data come from Danish national registries, which are among the most complete and reliably linked administrative databases in the world, and influenza was confirmed by PCR rather than self-report or clinical diagnosis alone. One limitation worth noting: the vaccine effect is measured through an interaction term, not a head-to-head randomized comparison — the mechanism (reduced viral load, reduced inflammatory response, direct vascular effects) is biologically plausible but cannot be definitively disentangled here. And with n=1,221, subgroup analyses by vaccine formulation or cardiovascular risk subtype are limited.

[WHO THIS HELPS] Most directly: adults over 65 — the median age in this cohort was approximately 75 — who are both at highest risk of serious influenza and highest risk of cardiovascular events. Also: patients with established coronary artery disease, heart failure, atrial fibrillation, or prior stroke, for whom even a relative risk increase of 2–4x could translate into a very real event. Globally, this finding is relevant wherever influenza circulates seasonally and cardiovascular disease is prevalent — which is to say, virtually everywhere. The equity dimension is important: populations with lower flu vaccination rates, including lower-income communities, Black and Hispanic adults in the United States, and populations in lower-income countries with limited vaccine access, bear the greatest combined burden of influenza and cardiovascular disease — and stand to gain the most from targeted vaccine outreach with a cardiovascular prevention framing.

[THE REAL-WORLD IMPACT] The flu vaccine is already recommended for older adults and those with cardiovascular disease in most major guidelines. What changes with this study is not the recommendation itself — it's the reason behind it. Cardiologists and primary care physicians can now frame the flu vaccine not just as infectious disease prevention but as a short-term cardiovascular risk intervention: every flu season, unvaccinated patients with heart disease are gambling with a ~5-fold spike in heart attack risk. That reframing could meaningfully move the needle on vaccination uptake in patients who have declined the vaccine on the grounds that they're "not worried about getting sick." There is also a plausible argument here for cardiovascular risk stratification in flu season management — should high-risk unvaccinated patients who develop influenza receive more intensive cardiovascular monitoring or prophylaxis during the 7-day high-risk window?

[WHAT WE STILL DON'T KNOW] The mechanism by which vaccination attenuates post-influenza cardiovascular risk is not fully resolved — candidates include reduced viral burden, blunted systemic inflammation, protection of vascular endothelium, and prevention of cytokine-mediated plaque instability. Whether specific vaccine formulations (high-dose, adjuvanted, or standard) differ in their cardiovascular protection is unknown. The study also cannot fully address whether the cardiovascular risk elevation in the 7-day window is attributable entirely to the infection itself or partly to the acute illness context (dehydration, physical stress, medication interruption). Finally, the Danish population is relatively ethnically homogeneous — whether these exact risk ratios translate to more diverse populations requires validation.

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High
• Translation Speed: Already in practice — this study strengthens and extends existing vaccine guidance; cardiovascular-framed messaging can begin immediately
• Barrier Analysis: No regulatory or infrastructure barriers. The main barrier is behavioral: vaccine hesitancy and under-prioritization of annual vaccination among older adults with cardiovascular disease. Healthcare system barriers include inconsistent clinical prompting and lack of cardiology-specific vaccine counseling. Equity barriers are meaningful — populations with the highest combined cardiovascular and influenza burden are often the hardest to reach through standard vaccine distribution channels.

[CALL TO ACTION / CLOSING] The flu shot has always been good medicine. But this study makes clear it's also, for many people, preventive cardiology — and that's a message that deserves to be heard at every annual physical, every cardiology follow-up, and every pharmacy window this coming flu season.